Summary
Thermo Fisher Scientific Inc. reported strong revenue growth of 6% for the first quarter of 2026, reaching $11.0 billion, driven by robust performance in the pharmaceutical and biotech sectors. While overall revenue saw a healthy increase, the academic and government, and diagnostics and healthcare markets experienced declines. The company demonstrated significant strategic activity with the acquisition of Clario Holdings, Inc. for $9.099 billion, expanding its clinical trial data solutions capabilities. Conversely, Thermo Fisher also announced the divestiture of its microbiology business for approximately $1.075 billion, expected to close in the second half of 2026. These strategic moves, alongside a substantial $3 billion in share repurchases and $0.16 billion in dividends paid, highlight the company's active capital allocation strategy.
Key Highlights
- 1Total revenues increased by 6% to $11.0 billion compared to the prior year's first quarter.
- 2The company completed a significant acquisition of Clario Holdings, Inc. for $9.099 billion to bolster its clinical trial data solutions.
- 3Thermo Fisher announced the planned divestiture of its microbiology business for approximately $1.075 billion, expected to close in late 2026.
- 4Share repurchases totaled $3.0 billion in the first quarter, demonstrating a commitment to returning capital to shareholders.
- 5Operating income grew by 9% to $1.9 billion, with an operating margin of 16.9%.
- 6Cash provided by operating activities increased significantly to $1.2 billion, and free cash flow more than doubled to $825 million.
- 7The company reported a substantial increase in goodwill on the balance sheet, largely driven by the Clario acquisition.